{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T14:41:00Z","timestamp":1792248060829,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ft\u0131rma Kurumu","doi-asserted-by":"publisher","award":["121C441"],"award-info":[{"award-number":["121C441"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002711","name":"Ahi Evran \u00dcniversitesi","doi-asserted-by":"publisher","award":["FEF.A3.24.004"],"award-info":[{"award-number":["FEF.A3.24.004"]}],"id":[{"id":"10.13039\/501100002711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-026-06282-0","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:53:05Z","timestamp":1792245185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetic Impact of CYP2C19 Variants on Diazepam Treatment Outcomes in Alcohol Withdrawal Syndrome"],"prefix":"10.1007","volume":"63","author":[{"given":"Selin","family":"\u00d6zkan-Kotilo\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan Can","family":"Tok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Dan\u0131\u015fman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukaddes Asena","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren H.","family":"Bozmao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Gumustas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130nci","family":"\u00d6zg\u00fcr-\u0130lhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Do\u011fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Sinan","family":"S\u00fczen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Kaya-Aky\u00fczl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"6282_CR1","unstructured":"Canver BR, Newman RK and Gomez AE (2024) Alcohol withdrawal syndrome. [Updated 2024 Feb 14]. In: StatPearls [Internet].StatPearls Publishing, Treasure Island (FL)"},{"key":"6282_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/add.15647","volume":"117","author":"E Day","year":"2022","unstructured":"Day E, Daly C (2022) Clinical management of the alcohol withdrawal syndrome. Addiction 117:804\u2013814. https:\/\/doi.org\/10.1111\/add.15647","journal-title":"Addiction"},{"key":"6282_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/01.NURSE.0000936760.82108.69","volume":"53","author":"RL Pullen Jr","year":"2023","unstructured":"Pullen RL Jr (2023) Alcohol withdrawal syndrome. Nursing 53:20\u201327. https:\/\/doi.org\/10.1097\/01.NURSE.0000936760.82108.69","journal-title":"Nursing"},{"key":"6282_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1708\/2925.29413","volume":"53","author":"F Attilia","year":"2018","unstructured":"Attilia F, Perciballi R, Rotondo C et al (2018) Alcohol withdrawal syndrome: diagnostic and therapeutic methods. Riv Psichiatr 53:118\u2013122. https:\/\/doi.org\/10.1708\/2925.29413","journal-title":"Riv Psichiatr"},{"key":"6282_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.annemergmed.2024.02.016","volume":"84","author":"M Gottlieb","year":"2024","unstructured":"Gottlieb M, Chien N, Long B (2024) Managing alcohol withdrawal syndrome. Ann Emerg Med 84:29\u201339. https:\/\/doi.org\/10.1016\/j.annemergmed.2024.02.016","journal-title":"Ann Emerg Med"},{"key":"6282_CR6","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/jnnp.2007.128322","volume":"79","author":"A McKeon","year":"2008","unstructured":"McKeon A, Frye MA, Delanty N (2008) The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry 79:854\u2013862. https:\/\/doi.org\/10.1136\/jnnp.2007.128322","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6282_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40263-016-0403-y","volume":"31","author":"SJ Weintraub","year":"2017","unstructured":"Weintraub SJ (2017) Diazepam in the treatment of moderate to severe alcohol withdrawal. CNS Drugs 31:87\u201395. https:\/\/doi.org\/10.1007\/s40263-016-0403-y","journal-title":"CNS Drugs"},{"key":"6282_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biom12121784","volume":"12","author":"MP Goldschen-Ohm","year":"2022","unstructured":"Goldschen-Ohm MP (2022) Benzodiazepine modulation of GABAA receptors: a mechanistic perspective. Biomolecules 12:1784. https:\/\/doi.org\/10.3390\/biom12121784","journal-title":"Biomolecules"},{"key":"6282_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1521-0391.2013.00307.x","volume":"22","author":"AJ Muzyk","year":"2013","unstructured":"Muzyk AJ, Leung JG, Nelson S (2013) The role of diazepam loading for the treatment of alcohol withdrawal syndrome in hospitalized patients. Am J Addict 22:113\u2013118. https:\/\/doi.org\/10.1111\/j.1521-0391.2013.00307.x","journal-title":"Am J Addict"},{"key":"6282_CR10","unstructured":"Dean L (2020) Diazepam therapy and CYP2C19 genotype. 2018 Dec 10 [Updated 2020 Oct 15]. In: Pratt VM, Scott SA, Pirmohamed M et al (eds) Medical genetics summaries [Internet]. National Center for Biotechnology Information (US), Bethesda (MD)"},{"key":"6282_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/jpm13020285","volume":"13","author":"TT Ho","year":"2023","unstructured":"Ho TT, Noble M, Tran BA et al (2023) Clinical impact of the CYP2C19 gene on diazepam for the management of alcohol withdrawal syndrome. J Pers Med 13:285. https:\/\/doi.org\/10.3390\/jpm13020285","journal-title":"J Pers Med"},{"key":"6282_CR12","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1021\/tx300192g","volume":"25","author":"N Isoherranen","year":"2012","unstructured":"Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I (2012) Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol 25:2285\u20132300. https:\/\/doi.org\/10.1021\/tx300192g","journal-title":"Chem Res Toxicol"},{"key":"6282_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113747","volume":"155","author":"P Zubiaur","year":"2022","unstructured":"Zubiaur P, Figueiredo-Tor L, Villapalos-Garc\u00eda G et al (2022) Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam. Biomed Pharmacother 155:113747. https:\/\/doi.org\/10.1016\/j.biopha.2022.113747","journal-title":"Biomed Pharmacother"},{"key":"6282_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.clpt.2005.08.020","volume":"78","author":"S Inomata","year":"2005","unstructured":"Inomata S, Nagashima A, Itagaki F et al (2005) CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther 78:647\u2013655. https:\/\/doi.org\/10.1016\/j.clpt.2005.08.020","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR15","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2019-0026","volume":"35","author":"VY Skryabin","year":"2020","unstructured":"Skryabin VY, Zastrozhin MS, Torrado MV et al (2020) How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome? Drug Metab Pers Ther 35:\/j\/dmdi.2020.35.issue-1\/dmpt-2019-0026\/dmpt-2019-0026.xml. https:\/\/doi.org\/10.1515\/dmpt-2019-0026","journal-title":"Drug Metab Pers Ther"},{"key":"6282_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1326776","volume":"15","author":"Q Shubbar","year":"2024","unstructured":"Shubbar Q, Alchakee A, Issa KW et al (2024) From genes to drugs: CYP2C19 and pharmacogenetics in clinical practice. Front Pharmacol 15:1326776. https:\/\/doi.org\/10.3389\/fphar.2024.1326776","journal-title":"Front Pharmacol"},{"key":"6282_CR17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fgene.2012.00206","volume":"3","author":"NA Helsby","year":"2012","unstructured":"Helsby NA, Burns KE (2012) Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19. Front Genet 3:206. https:\/\/doi.org\/10.3389\/fgene.2012.00206","journal-title":"Front Genet"},{"key":"6282_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1046\/j.0306-5251.2001.01499.x","volume":"52","author":"JA Goldstein","year":"2001","unstructured":"Goldstein JA (2001) Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 52:349\u2013355. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01499.x","journal-title":"Br J Clin Pharmacol"},{"key":"6282_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00228-016-2061-x","volume":"72","author":"M Jose","year":"2016","unstructured":"Jose M, Mathaiyan J, Kattimani S et al (2016) Role of CYP2C19 gene polymorphism in acute alcohol withdrawal treatment with loading dose of diazepam in a South Indian population. Eur J Clin Pharmacol 72:807\u2013812. https:\/\/doi.org\/10.1007\/s00228-016-2061-x","journal-title":"Eur J Clin Pharmacol"},{"key":"6282_CR20","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/03014460.2019.1687750","volume":"46","author":"NP Vu","year":"2019","unstructured":"Vu NP, Nguyen HTT, Tran NTB et al (2019) CYP2C19 genetic polymorphism in the Vietnamese population. Ann Hum Biol 46:491\u2013497. https:\/\/doi.org\/10.1080\/03014460.2019.1687750","journal-title":"Ann Hum Biol"},{"key":"6282_CR21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3109\/00498254.2015.1102986","volume":"46","author":"T Jin","year":"2016","unstructured":"Jin T, Zhang M, Yang H et al (2016) Genetic polymorphisms of the drug-metabolizing enzyme CYP2C19 in the Uyghur population in northwest China. Xenobiotica 46:634\u2013640. https:\/\/doi.org\/10.3109\/00498254.2015.1102986","journal-title":"Xenobiotica"},{"key":"6282_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.116805","volume":"260","author":"KC Tok","year":"2025","unstructured":"Tok KC, Ozkan-Kotiloglu S, Bozmaoglu CH et al (2025) Development of a sample preparation and analysis method for therapeutic monitoring of diazepam and major metabolite in alcohol withdrawal syndrome treatment. J Pharm Biomed Anal 260:116805. https:\/\/doi.org\/10.1016\/j.jpba.2025.116805","journal-title":"J Pharm Biomed Anal"},{"key":"6282_CR23","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1037\/0022-006x.56.6.893","volume":"56","author":"AT Beck","year":"1988","unstructured":"Beck AT, Epstein N, Brown G et al (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56:893\u2013897. https:\/\/doi.org\/10.1037\/0022-006x.56.6.893","journal-title":"J Consult Clin Psychol"},{"key":"6282_CR24","first-page":"163","volume":"12","author":"M Ulusoy","year":"1998","unstructured":"Ulusoy M, Sahin NH, Erkmen H (1998) turkish version of the beck anxiety inventory: psychometric properties. J Cogn Psychother 12:163\u2013172","journal-title":"J Cogn Psychother"},{"key":"6282_CR25","volume-title":"Manual for the beck depression inventory second edition (BDI-II)","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Brown G (1996) Manual for the beck depression inventory second edition (BDI-II). Psychological Corporation, San Antonio"},{"key":"6282_CR26","first-page":"3","volume":"7","author":"N Hisli","year":"1989","unstructured":"Hisli N (1989) Beck depresyon envanterinin universite \u00f6grencileri icin ge\u00e7erliligi, g\u00fcvenilirli\u011fi. Psikoloji Dergisi 7:3\u201313","journal-title":"Psikoloji Dergisi"},{"key":"6282_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Sykora K, Schneiderman J et al (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84:1353\u20131357. https:\/\/doi.org\/10.1111\/j.1360-0443.1989.tb00737.x","journal-title":"Br J Addict"},{"key":"6282_CR28","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","volume":"23","author":"BA Flannery","year":"1999","unstructured":"Flannery BA, Volpicelli JR, Pettinati HM (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23:1289\u20131295","journal-title":"Alcohol Clin Exp Res"},{"key":"6282_CR29","first-page":"70","volume":"22","author":"C Evren","year":"2011","unstructured":"Evren C, G\u00fcrol DT, \u00d6gel K et al (2011) Reliability and validity of the Penn Alcohol Craving Scale (PACS) Revised Version for substance craving in male substance dependent inpatients. Turk J Psychiatry 22:70","journal-title":"Turk J Psychiatry"},{"key":"6282_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/cpt.280","volume":"99","author":"LV Kalman","year":"2016","unstructured":"Kalman LV, Ag\u00fandez J, Appell ML et al (2016) Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther 99:172\u2013185. https:\/\/doi.org\/10.1002\/cpt.280","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2165\/00003088-200241120-00002","volume":"41","author":"Z Desta","year":"2002","unstructured":"Desta Z, Zhao X, Shin JG et al (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41:913\u2013958. https:\/\/doi.org\/10.2165\/00003088-200241120-00002","journal-title":"Clin Pharmacokinet"},{"key":"6282_CR32","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/0018578720931756","volume":"56","author":"VY Skryabin","year":"2021","unstructured":"Skryabin VY, Zastrozhin M, Torrado M et al (2021) Effects of CYP2C19*17 genetic polymorphisms on the steady-state concentration of diazepam in patients with alcohol withdrawal syndrome. Hosp Pharm 56:592\u2013596. https:\/\/doi.org\/10.1177\/0018578720931756","journal-title":"Hosp Pharm"},{"key":"6282_CR33","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/YPG.0000000000000306","volume":"32","author":"VY Skryabin","year":"2022","unstructured":"Skryabin VY, Zastrozhin M, Torrado M et al (2022) Effects of CYP2C19*17 genetic polymorphisms on plasma and saliva concentrations of diazepam in patients with alcohol withdrawal syndrome. Psychiatr Genet 32:67\u201373. https:\/\/doi.org\/10.1097\/YPG.0000000000000306","journal-title":"Psychiatr Genet"},{"key":"6282_CR34","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1046\/j.1365-2125.1996.42712.x","volume":"42","author":"J Wan","year":"1996","unstructured":"Wan J, Xia H, He N et al (1996) The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 42:471\u2013474. https:\/\/doi.org\/10.1046\/j.1365-2125.1996.42712.x","journal-title":"Br J Clin Pharmacol"},{"key":"6282_CR35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0009-9236(99)90075-9","volume":"66","author":"XP Qin","year":"1999","unstructured":"Qin XP, Xie HG, Wang W et al (1999) Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 66:642\u2013646. https:\/\/doi.org\/10.1016\/S0009-9236(99)90075-9","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR36","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1124\/dmd.115.064428","volume":"43","author":"AS Chaudhry","year":"2015","unstructured":"Chaudhry AS, Prasad B, Shirasaka Y et al (2015) The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism contributing to the poor metabolizer phenotype in livers with CYP2C19*35 and CYP2C19*2 alleles. Drug Metab Dispos 43:1226\u20131235. https:\/\/doi.org\/10.1124\/dmd.115.064428","journal-title":"Drug Metab Dispos"},{"key":"6282_CR37","doi-asserted-by":"publisher","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","volume":"269","author":"SM de Morais","year":"1994","unstructured":"de Morais SM, Wilkinson GR, Blaisdell J et al (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419\u201315422","journal-title":"J Biol Chem"},{"key":"6282_CR38","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cpt.2526","volume":"112","author":"CR Lee","year":"2022","unstructured":"Lee CR, Luzum JA, Sangkuhl K et al (2022) Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther 112:959\u2013967. https:\/\/doi.org\/10.1002\/cpt.2526","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","volume":"114","author":"CA Bousman","year":"2023","unstructured":"Bousman CA, Stevenson JM, Ramsey LB et al (2023) Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther 114:51\u201368. https:\/\/doi.org\/10.1002\/cpt.2903","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR40","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpt.597","volume":"102","author":"JK Hicks","year":"2017","unstructured":"Hicks JK, Sangkuhl K, Swen JJ et al (2017) Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102:37\u201344. https:\/\/doi.org\/10.1002\/cpt.597","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2009.03578.x","volume":"69","author":"A Li-Wan-Po","year":"2010","unstructured":"Li-Wan-Po A, Girard T, Farndon P et al (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol 69:222\u2013230. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03578.x","journal-title":"Br J Clin Pharmacol"},{"key":"6282_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","volume":"79","author":"SC Sim","year":"2006","unstructured":"Sim SC, Risinger C, Dahl ML et al (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103\u2013113. https:\/\/doi.org\/10.1016\/j.clpt.2005.10.002","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1365-2710.2007.00829.x","volume":"32","author":"T Fukasawa","year":"2007","unstructured":"Fukasawa T, Suzuki A, Otani K (2007) Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 32:333\u2013341. https:\/\/doi.org\/10.1111\/j.1365-2710.2007.00829.x","journal-title":"J Clin Pharm Ther"},{"key":"6282_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/genes14051095","volume":"14","author":"M Radosavljevic","year":"2023","unstructured":"Radosavljevic M, Svob Strac D, Jancic J et al (2023) The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. Genes (Basel) 14:1095. https:\/\/doi.org\/10.3390\/genes14051095","journal-title":"Genes (Basel)"},{"key":"6282_CR45","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"},{"key":"6282_CR46","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1021\/cn5000056","volume":"5","author":"NE Calcaterra","year":"2014","unstructured":"Calcaterra NE, Barrow JC (2014) Classics in chemical neuroscience: diazepam (valium). ACS Chem Neurosci 5:253\u2013260. https:\/\/doi.org\/10.1021\/cn5000056","journal-title":"ACS Chem Neurosci"},{"key":"6282_CR47","first-page":"1284","volume":"29","author":"K Kosuge","year":"2001","unstructured":"Kosuge K, Jun Y, Watanabe H et al (2001) Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status. Drug Metab Dispos 29:1284\u20131289","journal-title":"Drug Metab Dispos"},{"key":"6282_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1046\/j.1365-2125.2002.t01-10-01714.x","volume":"55","author":"SJ de Visser","year":"2003","unstructured":"de Visser SJ, van der Post JP, de Waal PP et al (2003) Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55:39\u201350. https:\/\/doi.org\/10.1046\/j.1365-2125.2002.t01-10-01714.x","journal-title":"Br J Clin Pharmacol"},{"key":"6282_CR49","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s13318-020-00614-8","volume":"45","author":"LL Wang","year":"2020","unstructured":"Wang LL, Ren XX, He Y et al (2020) Study on the pharmacokinetics of diazepam and its metabolites in blood of Chinese people. Eur J Drug Metab Pharmacokinet 45:477\u2013485. https:\/\/doi.org\/10.1007\/s13318-020-00614-8","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"6282_CR50","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.bbr.2011.12.013","volume":"228","author":"Y Zhao","year":"2012","unstructured":"Zhao Y, Wang Z, Dai J et al (2012) Beneficial effects of benzodiazepine diazepam on chronic stress-induced impairment of hippocampal structural plasticity and depression-like behavior in mice. Behav Brain Res 228:339\u2013350. https:\/\/doi.org\/10.1016\/j.bbr.2011.12.013","journal-title":"Behav Brain Res"},{"key":"6282_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","volume":"41","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89\u2013295. https:\/\/doi.org\/10.1080\/03602530902843483","journal-title":"Drug Metab Rev"},{"key":"6282_CR52","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/FPC.0b013e32834d4962","volume":"22","author":"SA Scott","year":"2012","unstructured":"Scott SA, Sangkuhl K, Shuldiner AR et al (2012) PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. Pharmacogenet Genomics 22:159\u2013165. https:\/\/doi.org\/10.1097\/FPC.0b013e32834d4962","journal-title":"Pharmacogenet Genomics"},{"key":"6282_CR53","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/cpt1978245600","volume":"24","author":"DJ Greenblatt","year":"1978","unstructured":"Greenblatt DJ, Allen MD, MacLaughlin DS et al (1978) Diazepam absorption: effect of antacids and food. Clin Pharmacol Ther 24:600\u2013609. https:\/\/doi.org\/10.1002\/cpt1978245600","journal-title":"Clin Pharmacol Ther"},{"key":"6282_CR54","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2165\/00003088-197803010-00005","volume":"3","author":"M Mandelli","year":"1978","unstructured":"Mandelli M, Tognoni G, Garattini S (1978) Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 3:72\u201391. https:\/\/doi.org\/10.2165\/00003088-197803010-00005","journal-title":"Clin Pharmacokinet"},{"key":"6282_CR55","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2174\/138920008786049258","volume":"9","author":"R Mandrioli","year":"2008","unstructured":"Mandrioli R, Mercolini L, Raggi MA (2008) Benzodiazepine metabolism: an analytical perspective. Curr Drug Metab 9:827\u2013844. https:\/\/doi.org\/10.2174\/138920008786049258","journal-title":"Curr Drug Metab"},{"key":"6282_CR56","unstructured":"Bounds CG, Patel P (2024) Benzodiazepines. [Updated 2024 Jan 30]. In: StatPearls [Internet]. 2025; StatPearls Publishing, Treasure Island (FL)"},{"key":"6282_CR57","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1046\/j.1365-2710.1999.00247.x","volume":"24","author":"E Tanaka","year":"1999","unstructured":"Tanaka E (1999) Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther 24:347\u2013355. https:\/\/doi.org\/10.1046\/j.1365-2710.1999.00247.x","journal-title":"J Clin Pharm Ther"},{"key":"6282_CR58","volume-title":"The benzodiazepines: current standards for medical practice","author":"DJ Greenblatt","year":"1985","unstructured":"Greenblatt DJ, Shader RI (1985) Clinical pharmacokinetics of the benzodiazepines. In: Smith DE, Wesson DR (eds) The benzodiazepines: current standards for medical practice. Springer, Dordrecht"},{"key":"6282_CR59","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/0165-6147(92)90140-2","volume":"13","author":"S Cholerton","year":"1992","unstructured":"Cholerton S, Daly AK, Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13:434\u2013439. https:\/\/doi.org\/10.1016\/0165-6147(92)90140-2","journal-title":"Trends Pharmacol Sci"},{"key":"6282_CR60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082562","volume":"8","author":"SC Preissner","year":"2013","unstructured":"Preissner SC, Hoffmann MF, Preissner R et al (2013) Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy. PLoS ONE 8:e82562. https:\/\/doi.org\/10.1371\/journal.pone.0082562","journal-title":"PLoS ONE"},{"key":"6282_CR61","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/sj.tpj.6500462","volume":"8","author":"D Tomalik-Scharte","year":"2008","unstructured":"Tomalik-Scharte D, Lazar A, Fuhr U et al (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4\u201315. https:\/\/doi.org\/10.1038\/sj.tpj.6500462","journal-title":"Pharmacogenomics J"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06282-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-026-06282-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:53:08Z","timestamp":1792245188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-026-06282-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["6282"],"URL":"https:\/\/doi.org\/10.1007\/s12035-026-06282-0","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval (\u013010-618\u201321) was obtained from Human Research Ethics Committee of Ankara University.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the authors used DeepL Write and ChatGPT to check grammatical errors and improve the fluency and readability of the manuscript. Having used these tools, the authors reviewed and edited the content as necessary, taking full responsibility for the published manuscript.","order":2,"name":"Ethics","label":"Generative AI and AI-Assisted Technologies in the Writing Process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"976"}}